There is a relationship between the metabolic syndrome and renal events, even in nondiabetic individuals. The presence of the metabolic syndrome has been associated with several traditional and new cardiovascular risk factors, such as intra-abdominal (visceral) obesity, as well as with early signs of subclinical cardiovascular and renal damage. This paper reviews the prevalence, mechanisms, prognostic significance, and treatment of the metabolic syndrome in patients with hypertension. Based on the evidence that cardiovascular disease risk increases when both the metabolic syndrome and hypertension are present, the European Society of Hypertension suggests that presence of metabolic syndrome components may affect therapeutic strategies in hypertensive individuals.
Documentation centre